Reynders McVeigh Capital Management LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Reynders McVeigh Capital Management LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,015 shares of the medical research company’s stock after purchasing an additional 165 shares during the period. Reynders McVeigh Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $4,116,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Thermo Fisher Scientific by 4.1% during the first quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock valued at $7,459,327,000 after purchasing an additional 1,074,400 shares during the last quarter. FMR LLC raised its holdings in shares of Thermo Fisher Scientific by 33.5% during the first quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock valued at $3,167,647,000 after purchasing an additional 2,900,868 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Thermo Fisher Scientific by 2.4% during the first quarter. Clearbridge Investments LLC now owns 3,089,195 shares of the medical research company’s stock valued at $845,574,000 after purchasing an additional 71,898 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Thermo Fisher Scientific by 22.9% during the second quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after purchasing an additional 555,802 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,706,326 shares of the medical research company’s stock valued at $605,651,000 after purchasing an additional 17,860 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Several analysts recently issued reports on the stock. BTIG Research boosted their target price on shares of Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research report on Thursday, May 23rd. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, May 30th. They set an “outperform” rating for the company. Needham & Company LLC boosted their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Credit Suisse Group restated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Finally, Argus boosted their target price on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $303.17.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the completion of the transaction, the chief executive officer now directly owns 342,193 shares in the company, valued at $97,466,832.19. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total transaction of $670,725.00. Following the completion of the transaction, the chief financial officer now owns 40,029 shares of the company’s stock, valued at $10,739,380.41. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,775 shares of company stock valued at $14,986,676. Company insiders own 0.45% of the company’s stock.

NYSE TMO traded down $8.81 during trading hours on Friday, hitting $269.36. 1,288,188 shares of the company’s stock traded hands, compared to its average volume of 1,484,825. The business’s fifty day moving average price is $284.07 and its two-hundred day moving average price is $272.87. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $111.44 billion, a P/E ratio of 23.74, a P/E/G ratio of 1.82 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 52 week low of $208.34 and a 52 week high of $305.45.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.01 by $0.03. The business had revenue of $6.32 billion during the quarter, compared to analyst estimates of $6.31 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The company’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 12.24 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be given a $0.19 dividend. The ex-dividend date is Monday, September 16th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Treasury Bonds

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.